Overview
We are currently seeking a Scientist Target Identification and Selection* to support our team in the research and development of innovative immunotherapeutic products. You will work in Tuebingen (Germany) in an interdisciplinary environment with colleagues from all research and preclinical/ clinical development departments. Your analytical reasoning and action-oriented style as well as your organization and communication skills will contribute to the team’s success.
Your mission
The job profile is focused on the target identification & selection for precision medicine, which will involve but is not limited to these tasks:
- You will be responsible for the identification and selection of novel tumor-specific HLA ligands to fuel Immatics’ internal and partnered target pipelines.
- You will utilize Immatics’ XPRESIDENT® target discovery platform to analyze a broad range of patient-individual as well as population-based Omics datasets (peptidomics, transcriptomics, genomics) and you will further research and include available relevant data into your selection process.
- You will join an interdisciplinary team of bioinformaticians, scientists and technology experts to develop new selection strategies. You will evaluate and support the integration of new technologies that will further optimize our target selection process.
- Ultimately you will identify the best immunotherapy targets for each tumor indication and patient with your scientific expertise, analytical thinking and passion to translate your research into clinical application.
Your profile
You hold a PhD degree in Life Sciences, Biotechnology, Medicine, Pharmacy or have been comparably educated and proven your scientific excellence and your ability to account for complex projects, ideally with a track record in cancer biology and/ or immunotherapy. You show a high motivation to translate your scientific findings into clinical development and application. You challenge yourself to develop new concepts and solutions to find the best possible targets and therapy for every patient. You enjoy working in an interdisciplinary team and with datasets from different scientific disciplines. Preferably, you have previous experience in large-scale data analysis and have already worked with relational databases. Knowledge in mass spectrometry and/ or next generation sequencing is also of advantage. You take careful processing and documentation of your results for granted. Your scientific excellence, extraordinary analytical competence as well as your excellent communication, writing and presentation skills in English (German is a plus) enable you to successfully contribute to projects as part of a team and to present your work internally or to external partners from the pharmaceutical and biotech industry.
Why us?
We are a committed and inspired team and cherish the collegial, highly motivated, and family-friendly atmosphere within Immatics. Our culture allows for a high level of originality, independent thinking, and initiative. We believe in supporting our employees’ professional and social skills: We enable them to join conferences and trainings as well as to enjoy our Immatics benefits – e.g., job bike, job ticket, Health Programs, childcare benefits, relocation allowance, Company summer and winter events.
Notice
*We value diversity and inclusion. Immatics N.V. and all Immatics subsidiaries are equal opportunity employers that evaluate qualified applicants without regard to race, color, national origin, religion, sex, age, marital status, disability, veteran status, sexual orientation, gender identity, or other characteristics protected by law.
About Us
Immatics combines the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors with the goal of enabling a robust and specific T cell response against these targets.
This deep know-how is the foundation for our pipeline of Adoptive Cell Therapies and TCR Bispecifics as well as our partnerships with global leaders in the pharmaceutical industry. We are committed to delivering the power of T cells and to unlocking new avenues for patients in their fight against cancer.
